## MRD Assessment in Multiple Myeloma: Progress and Challenges

(Article begins on next page)

21 July 2024

iris-AperTO

University of Turin's Institutional Research Information System and Open Access Institutional Repository

*Review*

# MRD Assessment in Multiple Myeloma: Progress and Challenges

Luca Bertamini, MD[1]*, Mattia D'Agostino, MD[1]*, Francesca Gay, MD, PhD[1]**

[1]Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

**Article Topic:** 'MRD Assessment in multiple myeloma: Challenges and Progress'

*These authors equally contributed to this manuscript and share first authorship.*

**Correspondence to:** Dr. Francesca Gay, Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3 - 10126 Torino, Italy; tel: +39 0116334279; fax: +39 0116334187 (E-mail: fgay@cittadellasalute.to.it).
ORCID ID: 0000-0002-8619-412X

**Keywords**: multiple myeloma; minimal residual disease (MRD); next-generation sequencing (NGS); next-generation flow (NGF); positron emission tomography/ computed tomography (PET/CT); mass spectrometry (MS)

*Text word count: 4025 words [revised manuscript]*
*Abstract word count: 235 words*
*Number of references: 63*
*Tables: 2 tables*
*Figure: 1 figure*

**Abstract**

**Purpose of review**. Over the last decade, the development of effective treatment approaches for multiple myeloma (MM) has been associated with higher response rates and longer survival. In patients who achieve complete response, several high sensitivity techniques have been studied to assess minimal residual disease (MRD) and detect residual neoplastic cells within the bone marrow (by flow cytometry or molecular biology techniques) or outside the bone marrow (by imaging or circulating disease markers in the peripheral blood). This is of utmost importance, since residual disease can drive clinical relapse. This review focuses on the progress made in the assessment of MRD in MM.

**Recent findings**. The achievement of MRD negativity after therapy is considered prognostically important for MM patients, and data from clinical trials and meta-analyses have confirmed that it is strongly associated with better survival. Along with well-known techniques, such as next-generation sequencing (NGS), next-generation flow (NGF) and positron emission tomography/computed tomography (PET/CT), other methods such as mass spectrometry (MS) and circulating tumor cells are under study. Intensive treatment regimens at diagnosis can lead up to 70% of MRD negativity in MM patients, although the current proportion of curable patients is still unknown.

**Summary**. Today, clinicians who treat MM deal with MRD assessment in routine clinical practice. Its appropriate use in therapeutic decision making may be the most fascinating and challenging issue to be addressed over the next few years.

## Introduction

The introduction of 3- and 4-drug regimens with or without autologous stem-cell transplantation (ASCT) led to unprecedented response rates in patients with newly diagnosed multiple myeloma (NDMM). A large number of studies showed that an improved depth of response was associated with a superior overall survival (OS) and progression-free survival (PFS) [1].

With more than 50% of patients achieving conventionally defined complete responses (CR) with novel treatments, new techniques to measure residual disease at high sensitivity level within and outside the bone marrow (BM) have been developed to further classify patients into 2 groups: patients with measurable minimal residual disease (MRD positive) or without it (MRD negative) [2].

The International Myeloma Working Group (IMWG) revised the MM response criteria in 2015 and introduced, as a result of the progressive evolution of both imaging and BM techniques, the definition of MRD in patients who have achieved a CR as the persistence or re-emergence of very low levels of cancer cells [3].

Several investigators measured MRD by using different technologies and various time points during MM treatment, thus posing a challenge to the data interpretation of MM clinical trials. International consensus statements for the harmonization in assessing and reporting MRD in MM clinical trials have been recently published [4].

In this work, we have summarized the progress made in measuring MRD in MM and the new challenges emerging from the use of this powerful tool that it is now available to MM treating physicians.

## Measurement of MRD

*What we know: MFC, NGS and PET/CT*

Traditionally, the identification of MRD after therapy relied on the detection of residual malignant plasma cells in the BM by multiparameter flow cytometry (MFC) and molecular biology and the combined analysis of extramedullary disease (EMD) with positron emission tomography/computed tomography (PET/CT).

MFC exploits the particular phenotype of the tumor cell by analyzing the expression of surface antigens that are typical of plasma cells (CD138 and CD38) or aberrant markers (CD20, CD56, CD19, CD45, CD27,CD28, CD33, and CD117) and by analyzing the monoclonal expression of intra-cytoplasmic markers (intracellular κ or λ chains) [5]. The most updated version of MFC can be performed with 8-color 2-tube or 10-color 1-tube assays, which can lead to a high sensitivity of $10^{-5}$-$10^{-6}$ (1 cell per 100 000/1 million). The EuroFlow Consortium proposed a standardization of the MFC-MRD evaluation called Next-Generation Flow Cytometry (NGF), aimed at achieving higher sensitivity and quality of the MRD data [6]. Comparing MFC by conventional 8-color flow with NGF, Flores-Montero et al. showed that the latter technique identified residual disease in 25% of the patients who were classified as MRD-negative by standard MFC [7]. NGF requires the evaluation of 10 million events ($10^7$) and is applicable to roughly 100% of samples. Automatic plasma cell gating may avoid individual assessments and improve reproducibility [8]. A sensitivity of $10^{-6}$ can be achieved with some caveats, such as the presence of hemodiluted samples that are inadequate for MRD assessment (although sample quality can be evaluated during the analysis).

Molecular biology techniques take advantage of the immunoglobulin (Ig) gene rearrangement, which is a genetic marker for clonal plasma cells. This molecular footprint can be sequenced at diagnosis and then tracked throughout the clinical course after therapy. Allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) showed promising results [9–11], but

with some limits of applicability (40- 60%) due to the failure of Ig rearrangement identification after Ig somatic hypermutation and the need for patient-specific reagents [12]. Next-generation sequencing (NGS) recently overcame these limits, with higher applicability due to a better marker identification rate at diagnosis (90–92%) and a stronger prognostic impact. [13] After DNA is extracted from the BM sample, IgH, IgK, and IgL (immunoglobulin heavy, κ, and λ) genes are amplified and then sequenced by PCR, creating a sequencing library. Sequence reads that are identical to each other are defined as clonotypes and, when they occur at a frequency ≥5%, they are considered markers of clonality and can be used as markers for MRD follow-up. To do that, a bioinformatic tool and a certain degree of expertise are needed.

Over the past 2 decades, several imaging techniques have been implemented to help clinicians detect osteolytic lesions and focal lesions that are critical for the differential diagnosis between MM and other gammopathies [14]. $^{18}$F-Fluorodeoxyglucose (FDG) PET/CT is one of the most accurate and sensitive methods that can help identify both bone and extramedullary myeloma lesions at diagnosis, as well as give a functional information about FDG uptake, making possible to evaluate the disease after therapy [15]. The incidence of EMD depends on the methods used to detect disease outside the BM; paraskeletal EMD occurs in ~7-34% of patients, while extraosseous EMD (in soft tissues) in 1-4% of patients [16]. Indeed, MM is a patchy disease with multiple sites of bone involvement and spatial heterogeneity [17], and the assessment of BM MRD can lead to biased evaluations. To overcome these false-negative MRD evaluations, the IMWG response criteria (2016) clearly defined "imaging MRD" as the disappearance of every area of increased tracer uptake found at baseline or in a preceding PET/CT [3].

*Progress: comparison of techniques and novel methods*
The availability of different techniques raises the question of the comparison among them in terms of applicability, cost, prognostic power, and concordance. Nowadays, ASO-PCR and MFC have been superseded by NGS and NGF, which, despite some limitations, are more sensitive and standardized. Advantages of MFC/NGF are their wide applicability, feasibility without a baseline diagnostic sample, and rapid turnaround time (3-4 hours). The drawback is mainly the need for fresh samples. Advantages of NGS are the possibilities to use both fresh and stocked samples and to track clonal evolution. On the other hand, drawbacks are that NGS requires a baseline sample and that only one platform is validated (clonoSEQ®, Adaptive Biotechnologies, US-WA). Other academic NGS platforms are less standardized and require a valid bioinformatic support. FDG PET/CT seems to be complementary to these two BM MRD techniques (NGS and NGF/MFC), due to its ability to track focal lesions and EMD. PET/CT requires nuclear medicine expertise and adequate facilities. Moreover, a drawback of FDG PET is that ~10% of patients with residual MM may achieve a false-negative imaging MRD status due to low levels of the enzyme hexokinase that reduce FDG uptake in neoplastic plasma cells [18]. This limitation can be overcome by using alternative PET tracers that do not rely on hexokinase. One of the most promising PET tracers is 11C-methionine, whose uptake correlates with protein synthesis (very active in MM cells). In a head-to-head comparison in a heterogeneous MM patient population, the use of 11C-methionine with PET/CT was more sensitive than FDG in detecting focal lesions [19].

The most intriguing question concerns the prognostic impact of the achievement of MFC-MRD negativity, as compared with NGS-MRD and imaging MRD. Some head-to-head comparison studies have been designed to assess differences and similarities in these terms (Table 1). Ongoing clinical trials are reporting good concordance between clonoSEQ® NGS and MFC. Oliva et al. reported 86% of correlation with MRD at a sensitivity of 10$^{-5}$ in ≥CR patients in the phase II multicenter randomized FORTE trial [20]. Similar data come from the phase III CASSIOPEIA trial, with 83.5% of concordance between MFC and NGS with a sensitivity of 10$^{-5}$ [21]. A direct

comparison between NGF and NGS was reported [22], but there is a lack of data on the comparison between NGF and NGS with clonoSEQ® platform.

A comparison between PET/CT and BM MRD techniques was explored in a substudy on 133 patients of the FORTE trial. Data reported by Zamagni et al. showed good concordance between PET/CT and NGS (84%) and between PET/CT and MFC (93%) at $10^{-5}$ in the identification of BM residual disease. By contrast, there was discrepancy in the assessment of residual disease in patients with focal lesions, with disagreement in ~33-37% of cases [23]. These data support the hypothesis that PET/CT MRD evaluation and BM evaluation are not mutually exclusive, but complementary.

In addition to PET/CT, other strategies are under development to overcome some limitations of BM MRD evaluation. First, the analysis of peripheral blood (PB) to detect residual disease represents an appealing approach to overcome both MM spatial heterogeneity and the false-negative MRD evaluations due to BM specimen hemodilution. Both NGS and flow cytometry have been studied on PB samples, following the concept of liquid biopsy.

Circulating plasma cells (CPC) can be detected in the majority of MM patients at diagnosis, can be tracked during the disease course and have a prognostic impact [24]. Although a sensitive technology such as NGF identifies CPC in almost all MM patients at diagnosis, it seems to be less sensitive than BM NGF residual disease detection. Sanoja-Flores et al. compared MRD with NGF in BM and PB after therapy in a real-world case series of 137 patients. Using NGF, CPC were persistent after therapy in 26% of patients. While all CPC-positive patients had BM MRD-positive disease, 40% of patients who were BM MRD-positive showed undetectable CPC (PB MRD negativity), thus suggesting that CPC is a less sensitive MRD marker than BM MRD [25].

Similar findings were reported in the analysis of circulating tumor DNA (ctDNA) using NGS. Mazzotti et al. analyzed a small prospective series of 37 MM patients, whose paired BM and PB samples were analyzed to detect MRD. Again, a concordance of only 49% was found, with the majority of discordant cases being BM MRD positive and PB MRD negative. Only 1 case was BM MRD negative and PB MRD positive, without any sign of hemodilution and no extramedullary residual lesions detected by PET/CT, likely due to patchy MM infiltration in this patient [26].

The use of novel technologies, such as mass spectrometry (MS), to measure the monoclonal (M)-protein produced by clonal plasma cells is emerging. Historically, response to therapy has been observed by monitoring the reduction of M-protein via serum protein electrophoresis (SPEP) and the more sensitive serum immunofixation (s-IFX). MS is an ultra-sensitive technique that may potentially supersede the above-mentioned methods. Indeed, MS can be used to detect the unique mass of clonal M-protein and to monitor its presence during disease over time in the PB. Different methods of MS are under study: clonotypic peptide methods and intact protein methods. Clonotypic peptide methods are quite complex and use enzyme digested-peptides from M-protein as a surrogate marker of disease and require baseline M-protein and BM samples. Intact proteins methods, also known as monoclonal Ig rapid accurate mass measurements (miRAMM), measure the accurate mass of the intact light chain to track residual disease and need only a small amount of baseline serum sample [27]. Clonotypic MS methods were compared to BM MRD by NGS in a small subgroup of patients enrolled in the IFM 2009 study, showing a good concordance of 78% (64/82) [28]. Quantitative immunoprecipitation mass spectrometry (QIP-MS) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) are the most common intact Ig techniques developed so far. QIP-MS showed higher sensitivity when compared to standard SPEP and good concordance with BM NGF evaluation, as reported in the GEM-CESAR trial [29]. Interestingly, approximately 80% of the patients who were QIP-MS negative were also BM NGF negative; on the other hand, 20% of QIP-MS-positive patients were BM NGF negative, possibly due to patchy MM infiltration or EMD.

The MALDI-TOF technique recently showed higher sensitivity than s-IFX [30] and a concordance of 62% with BM flow-MRD results[31], but it was less sensitive than other MS methods. However, in a study reported by Abeykoon et al., the M-protein was still detectable by MALDI-TOF in 59% of patients who achieved a conventionally defined CR and were NGF-MRD negative after 100 days from ASCT [32].

Magnetic Resonance Imaging (MRI) is broadly used for diagnosis in MM due to its high sensitivity (particularly in detecting BM plasma cell infiltration and bone lesions), but it has never been validated for residual disease detection and is inferior to PET/CT. This inferior performance in tracking disease response seems to be related to the slower disappearance of MM focal lesions and to the inability of MRI to discriminate between scar tissue and normal tissue [33]. A novel technique known as whole-body diffusion-weighted imaging (DWI) MRI overcame these limitations and had results that were similar to PET/CT [34, 35].

*Challenges: standardization and optimization*
In the last 10 years, a substantial amount of literature and data on MRD has been published, and MRD assessment has been included in almost all clinical trials. However, there is a large diversity in MRD methods, procedures, sensitivity, and time points of evaluation and report. This definitely stresses the importance of a methodological standardization and a consensus about the data analysis [4].

Regarding the analytical standardization, efforts on the development of MFC have been made by EuroFlow, leading to the definition of NGF. Regarding NGS, even if clonoSEQ® is currently the only platform that received the quality approval for commercial use from the Food and Drug Administration (FDA), different platforms have been proposed. Euroclonality-NGS Consortium, an international expert laboratory network, recently developed an Ig and T-cell receptor NGS protocol corroborated by quality control studies [36–38]. Furthermore, some single-center academic platforms are under development (e.g., LymphoTrack®, Invivoscribe, Inc., US-CA) [39, 40].

Moreover, the MRD assay should be analytically validated with defined parameters expressing the accuracy of the MRD report in terms of limit of blank (LOB), limit of quantification (LOQ), limit of detection (LOD), and MRD threshold. An expert consensus stated that the minimum threshold for defining MRD negativity should be at least of $10^{-5}$ [4].

Similarly, for PET/CT, there is a lack of recognized cut-off values for positivity and negativity, which are essential for data interpretation. A first attempt to define response criteria was proposed by an Italian group of nuclear medicine experts (Italian Myeloma Criteria for PET Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients [41, 42]. Zamagni et al. recently reported data from a pooled analysis of 226 patients treated with novel agents, transplant, and maintenance therapy in 2 phase III trials (IFM/DFCI2009 and EMN02/HO65). $^{18}$FDG PET/CT was performed at diagnosis and before maintenance therapy, applying the Deauville score (DS, which is validated for lymphomas) to describe BM uptake and focal lesions. DS ≥4 after treatment in both BM and focal lesions had a strong prognostic impact and was proposed as a cut-off for the definition of PET MRD positivity [43].

Another important issue concerns the optimal time point to assess MRD and the possible repetition of MRD testing in case of previous achievement of MRD negativity. On the one hand, it is important to avoid unnecessary examinations that can be difficult to implement in the clinical practice. On the other hand, confirming MRD status during the course of therapy is equally important, because even MRD-negative patients can relapse, and the persistence of MRD negativity (i.e., "sustained MRD negativity") is strongly associated to better outcome [44, 45].

Generally, there is great heterogeneity in terms of when MRD testing is performed. In transplant-eligible patients, the treatment phases (induction, ASCT, consolidation, and maintenance) give the opportunity to evaluate MRD at fixed time points (e.g., before or after a specific phase). Conversely, in transplant-ineligible patients, continuous therapy is commonly used, and no standard timing has consequently been established for MRD assessment, which can be performed at specific time points (e.g., after 1 or 2 years of treatment) or can be tested together with the CR confirmation in the absence of M-component. Indeed, likely due to the long M-component half-life, many patients who are still in very good partial response (VGPR) may achieve MRD negativity in the BM before the M-component is cleared. Thus, many studies tested MRD in VGPR patients rather than in CR patients. However, M-protein production from patchy infiltration or extramedullary sites cannot be ruled out even in the presence of MRD negativity.

Data coming from clinical trials evaluating MRD at multiple time points using different techniques (NGF, NGS, Imaging, liquid biopsy) will inform us on the best timing and criteria to test and measure MRD.

**Aims of MRD**

As already pointed out, MRD is probably the most important prognostic factor in MM patients [1]. The achievement of MRD negativity predicts longer PFS and OS (as compared with conventionally-defined CR) [46] and, particularly in the case of sustained MRD negativity, may overcome the negative prognostic impact conferred by high-risk features detected at baseline [8].

Moreover, MRD is now being considered the best candidate as surrogate endpoint to be used in clinical trials to obtain regulatory approval of new combination therapies in MM. Ideally, the best endpoints to obtain regulatory approval are OS [47] and patient-reported outcomes. However, as survival of MM patients improved, PFS has been widely used as a surrogate endpoint for OS, since data can be provided in a more feasible time frame. Nevertheless, thanks to the availability of new drug combinations, PFS of newly diagnosed MM patients is now longer. For this reason, now it takes considerable time and a large cohort of patients to detect differences in terms of PFS between different treatments, and this can lead to delayed drug approval. Therefore, MRD is now being evaluated as a surrogate endpoint. The determination of MRD endpoint surrogacy for OS and PFS requires a robust analysis using data from several clinical trials. This task is being pursued by the International Independent Team for Endpoint Approval of Myeloma MRD (I2TEAMM) [48].

There are limitations to the use of MRD negativity as a surrogate endpoint for OS/PFS: (1) there is no consensus on the optimal timepoint to measure MRD; (2) a proportion of patients may achieve MRD negativity but still relapse early [49]; (3) there is no consensus on the need to repeat MRD evaluation over time and on the optimal duration of sustained MRD negativity; (4) some patients with an MGUS-like profile may not achieve MRD negativity but may still have a very indolent disease course without experiencing relapse; (5) MRD might not be an achievable therapeutic endpoint in patients in whom treatment options are limited by low treatment tolerance (e.g., frail patients) [50, 51]; (6) finally, one of the most important limitations is that, differently from OS/PFS, MRD does not take into account deaths. For instance, in the BELLINI trial evaluating venetoclax or placebo in combination with bortezomib-dexamethasone in relapsed/refractory MM patients, MRD negativity at a sensitivity of $10^{-5}$ was significantly higher in the experimental arm than in the control arm (13% vs. 1%), although a trend towards a worse survival was observed in the experimental arm due to an increased rate of infections [52]. A composite endpoint including MRD and a safety evaluation may overcome this limitation.

Another key question is whether we can use MRD to guide treatment in MM. For example, we know that MRD-positive patients with high-risk disease at baseline have a very dismal outcome [8], thus posing the question of whether these patients may benefit from a treatment intensification in case of residual disease detection after standard treatment in order to convert them to MRD negative.

On the other hand, although maintenance/continuous therapy is a mainstay of MM treatment, its optimal duration and the possibility to include 1 vs. more than 1 drug [53] in this phase remain to be determined [54, 55]. Achieving MRD negativity and maintaining MRD-negative status has the potential to guide treatment deintensification without affecting patient outcome. This is important because treatment-free interval is crucial for patients. Furthermore, MM therapies are becoming more and more expensive. Avoiding unnecessary treatment may improve quality of life, spare patients from unwarranted toxicity, and help the health care system save money associated with years of excessive treatment.

Selected trials evaluating MRD-driven therapeutic modifications are summarized in Table 2.

Measuring MRD at high sensitivity thresholds and finding patients negative on repeated evaluations also raise the question of whether these patients may be cured [56]. If MRD is measured in a treatment exploring curative approaches (e.g., intensive treatment of high-risk smoldering MM) [57], the sensitivity threshold should be as high as possible (ideally, at least $10^{-6}$ in the BM, probably more in the PB), and the residual disease should not be found with any technique, either in the BM or in the PB. Moreover, in this scenario, 1 MRD time point would not be enough, and the elimination of residual disease should be controlled over time. Long-term follow-ups of the initial trials exploring MRD will suggest the optimal duration of MRD negativity to achieve sustained remissions and, possibly, cure.

## Conclusions

Currently, the main challenges in MRD evaluation are the standardization of the available techniques (NGF, NGS, liquid biopsy, and PET/CT) and their comparison, to determine which one is the better in each setting, and which ones are actually complementary to each other. Regarding imaging techniques, PET/CT limitations could be overcome by new, better tracers [58] corroborated by improved and standardized response criteria. The possibility to have standardized analyses as well as uniform reporting standards for response is a key step towards study comparison and the use of MRD as an endpoint for drug approval [4].

Another future challenge will be the implementation of MRD in MM clinical practice. To do that, it will be essential to simplify MRD testing by identifying the most important time point for MRD measurement. This would also reduce costs and avoid unnecessary BM sampling or PET/CT assessment.

Data from trials assessing all MRD methods at different timepoints (e.g., EMN18, EMN24, and many others) will foster the development of an algorithm to determine the use of the most appropriate technique at the right time point in each subset of patients.

Clinical presentation of MM may possibly drive MRD testing (Fig. 1). At baseline, all patients should ideally receive PET/CT and BM evaluation. Since PB MRD testing is less sensitive than BM, it could be used to first assess the depth of response (by MS or NGF/NGS). PB MRD negativity could be used to guide the timing of BM analysis and/or imaging according to patient status at baseline. For instance, if patients with only skeletal BM disease (no baseline EMD or focal lesions at PET/CT; Fig. 1A) are MRD negative, then they may be candidate for BM MRD assessment, since there is good concordance between PET/CT and BM MRD in patients with BM uptake [23]. In this case, if BM MRD is negative and the patient is at low risk, then it is possible to monitor MRD in PB to reduce the number of BM biopsies. On the other hand, patients with focal lesions (Fig. 1B) or EMD who achieve PB MRD negativity could be monitored with PET/CT together with BM evaluation, since these techniques seem to be complementary in this

setting. In the future, with more sensitive techniques, we might track EMD with liquid biopsy PB assays (MS, NGS, and NGF). In case of circulating tumor cells detected by flow cytometry at diagnosis (Fig. 1C), it could be interesting to monitor MRD first in the PB via NGF and then in the BM after the disease is eliminated in the PB.

As reported by Paiva et al., patients with BM MRD negativity at a sensitivity of $10^{-6}$ with NGF could still relapse, and the majority of them have high-risk features, either high-risk chromosomal abnormalities, elevated lactate dehydrogenase, or International Staging System stage II/III. Moreover, many of them relapsed without M-protein or BM infiltration [8]. As a consequence, these high-risk patients should likely be followed with at least two methods (BM and PET/CT or PB and PET/CT). On the other hand, the achievement of MRD negativity in the BM at high sensitivity may overcome the poor prognosis predicted by high-risk features detected at diagnosis [8].

Beyond the evaluation of the best monitoring strategies, the subsequent challenge will be to define how to use MRD to guide treatment, escalating therapy in the presence of residual disease and/or reducing intensity after the achievement of sustained MRD negativity, particularly during the maintenance phase.

To conclude, it is crystal clear that MRD is and will be an integral part of MM care in the future, enhancing our ability to understand the clinical course of this disease, to design better treatment strategies and improve the care of MM patients.

**Key references**
*important reference
**very important reference

**1. Munshi NC, Avet-Loiseau H, Anderson KC, et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4:5988–5999
**A recent meta-analysis on around 8000 patients from different MRD studies, confirming the important prognostic impact of the achievement of MRD negativity, regardless of the adopted method (next-generation sequencing [NGS] or multiparameter flow cytometry [MFC]), time point, and setting (diagnosis or relapse).**

**4. Costa LJ, Derman BA, Bal S, et al (2021) International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 35:18–30
**An international expert consensus on how to report MRD analysis, to foster the standardization and comparison among different studies.**

*25. Sanoja-Flores L, Flores-Montero J, Puig N, et al (2019) Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 134:2218–2222
*26. Mazzotti C, Buisson L, Maheo S, et al (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811–2813
**Two papers that focus on peripheral blood (PB) MRD assessment with next-generation flow (NGF, Sanoja-Flores et al.) and next-generation sequencing (NGS, Mazzotti et al.), as compared with bone marrow (BM) MRD assessment. Up to now, these data have revealed a lower sensitivity and inferiority of PB assessment compared to BM assessment.**

*27. Murray DL, Puig N, Kristinsson S, et al (2021) Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders : an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J
**A first report of the International Myeloma Working Group (IMWG) on the possible role of mass spectrometry (MS) in plasma cell disorders.**

*43. Zamagni E, Nanni C, Dozza L, et al (2021)  Standardization of 18 F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma . J Clin Oncol 39:116–125

**An important step towards the standardization of positron emission tomography/computed tomography (PET/CT) response assessment. In a pooled analysis of two phase III trials, Zamagni et al. pinpointed the prognostic impact of response by PET/CT following the Deauville criteria.**

### References

1. Munshi NC, Avet-Loiseau H, Anderson KC, et al (2020) A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 4:5988–5999
2. Oliva S, D'Agostino M, Boccadoro M, Larocca A (2020) Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. Front Oncol. https://doi.org/10.3389/fonc.2020.00001
3. Kumar S, Paiva B, Anderson KC, et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346
4. Costa LJ, Derman BA, Bal S, et al (2021) International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 35:18–30
5. Flores-Montero J, de Tute R, Paiva B, et al (2016) Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 90:61–72
6. Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC (2016) Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom 90:26–30
7. Flores-Montero J, Sanoja-Flores L, Paiva B, et al (2017) Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31:2094–2103
8. Paiva B, Puig N, Cedena MT, et al (2020) Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 38:784–792
9. Ladetto M, Pagliano G, Ferrero S, et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28:2077–2084
10. Gambella M, Omedé P, Spada S, et al (2019) Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer 125:750–760
11. Puig N, Sarasquete ME, Balanzategui A, et al (2014) Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 28:391–397
12. Avet-Loiseau H (2016) Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. Am Soc Clin Oncol Educ B 36:e425–e430
13. Perrot A, Lauwers-Cances V, Corre J, et al (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456–2464
14. Hillengass J, Usmani S, Rajkumar SV, et al (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302–e312
15. Cavo M, Terpos E, Nanni C, et al (2017) Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus

statement by the International Myeloma Working Group. Lancet Oncol 18:e206–e217

16. Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ (2020) Extramedullary multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-019-0660-0

17. Rasche L, Chavan SS, Stephens OW, et al (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:1–10

18. Rasche L, Angtuaco E, McDonald JE, et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. Blood 130:30–34

19. Lapa C, Garcia-Velloso MJ, Lückerath K, et al (2017) 11C-Methionine-PET in multiple myeloma: A combined study from two different institutions. Theranostics 7:2956–2964

20. Oliva S, Genuardi E, Belotti A, et al (2020) Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). J Clin Oncol 38:Abstract #8533 [ASCO 2020 Annual Meeting]

21. Avet-Loiseau H, Bene MC, Wuilleme S, et al (2019) Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA. Clin Lymphoma, Myeloma Leuk 19:e3–e4

22. Medina A, Puig N, Flores-Montero J, et al (2020) Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 10:108

23. Zamagni E, Nanni C, Gay F, et al (2020) MRD EVALUATION BY PET/CT ACCORDING TO DEAUVILLE CRITERIA COMBINED WITH BONE MARROW TECHNIQUES IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS ENROLLED IN THE PHASE II FORTE TRIAL. HemaSphere 4:60 [Abstract #S207, EHA 2020 25th Congress]

24. Bertamini L, Grasso M, D'Agostino M, et al (2020) Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity. Blood 136:12-13 [Abstract #720, ASH 2020 62nd Meeting]

25. Sanoja-Flores L, Flores-Montero J, Puig N, et al (2019) Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood 134:2218–2222

26. Mazzotti C, Buisson L, Maheo S, et al (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811–2813

27. Murray DL, Puig N, Kristinsson S, et al (2021) Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders : an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J 4–9

28. Zajec M, Langerhorst P, Noori S, et al (2020) Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow. Blood 136:9 [Abstract #3156, ASH 2020 62nd Meeting]

29. Puíg N, Contreras T, Paiva B, et al (2020) Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS). J Clin Oncol 38:8512

30. Nandakumar B, Murray DL, Dispenzieri A, et al (2020) Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood 136:12–13

31. Eveillard M, Rustad E, Roshal M, et al (2020) Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for

tracking measurable residual disease in patients with multiple myeloma. Br J Haematol. https://doi.org/10.1111/bjh.16443

32. Abeykoon JP, Murray DL, Murray I, et al (2020) Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. https://doi.org/10.1111/bjh.17195

33. Walker R, Barlogie B, Haessler J, et al (2007) Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. J Clin Oncol 25:1121–1128

34. Latifoltojar A, Hall-Craggs M, Rabin N, et al (2017) Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol 176:222–233

35. Messiou C, Hillengass J, Delorme S, et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma response assessment and diagnosis system (MY-RADS). Radiology 291:5–13

36. Brüggemann M, Kotrová M, Knecht H, et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241–2253

37. Scheijen B, Meijers RWJ, Rijntjes J, et al (2019) Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 33:2227–2240

38. Knecht H, Reigl T, Kotrová M, et al (2019) Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33:2254–2265

39. Martinez-Lopez J, Sanchez-Vega B, Barrio S, et al (2017) Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia 31:1446–1449

40. Arcila ME, Yu W, Syed M, et al (2019) Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. J Mol Diagnostics 21:330–342

41. Nanni C, Zamagni E, Versari A, et al (2016) Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43:414–421

42. Nanni C, Versari A, Chauvie S, et al (2018) Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45:712–719

43. Zamagni E, Nanni C, Dozza L, et al (2021) Standardization of 18 F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma . J Clin Oncol 39:116–125

44. Avet-Loiseau H, San-Miguel J, Casneuf T, et al (2021) Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol 39:1139–1149

45. Kaufman JL, Laubach JP, Sborov D, et al (2020) Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood 136:45–46

46. Lahuerta J-J, Paiva B, Vidriales M-B, et al (2017) Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol 35:2900–2910

47. U.S. Department of Health and Human Services - Food and Drug Administration (2018)

Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Guidance for Industry. Silver Spring, US-MD

48. Holstein SA, Al-Kadhimi Z, Costa LJ, et al (2020) Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 26:e7–e15

49. D'Agostino M, Zaccaria GM, Ziccheddu B, et al (2020) Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. Clin Cancer Res 26:4832–4841

50. Larocca A, Dold SM, Zweegman S, et al (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32:1697–1712

51. Salvini M, D'Agostino M, Bonello F, Boccadoro M, Bringhen S (2018) Determining treatment intensity in elderly patients with multiple myeloma. Expert Rev Anticancer Ther 18:917–930

52. Kumar SK, Harrison SJ, Cavo M, et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630–1642

53. Gay F, Musto P, Rota Scalabrini D, et al (2020) Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood 136:35-37 [Abstract #141, ASH 2020 62nd Meeting]

54. D'Agostino M, De Paoli L, Conticello C, et al (2018) Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol 132:9–16

55. Larocca A, Bonello F, Gaidano G, et al (2021) Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. Blood Article in press, accepted for publication

56. D'Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F (2019) Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies. Cancers (Basel). https://doi.org/10.3390/cancers11122015

57. Mateos M-V, Martinez-Lopez J, Rodriguez Otero P, et al (2019) Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood 134:Abstract #781 [ASH 2019 61st Meeting]

58. Pandit-Taskar N (2018) Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. Semin Hematol 55:22–32

59. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123:3073–3079

60. Kriegsmann K, Hundemer M, Hofmeister-Mielke N, et al (2020) Comparison of ngs and mfc methods: Key metrics in multiple myeloma mrd assessment. Cancers (Basel) 12:1–15

61. Rodríguez S, Goicoechea I, Gemenetzi K, et al (2020) Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. Blood 136:5-6 [Abstract #62, ASH 2020 62nd Meeting]

62. Sonneveld P, Broijl A, Gay F, et al (2019) Bortezomib, lenalidomide, and dexamethasone

(VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). J Clin Oncol 37:Abstract #TPS8055 (ASCO 2019 Annual Meeting]

63. Costa LJ, Chhabra S, Godby KN, et al (2019) Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myelo. Blood 134:Abstract #860 [ASH 2019 61st Meeting]

**Tables**

**Table 1** Head-to-head comparison of different techniques for MRD analysis

| | TRIAL | N of pts | Sensitivity | Concordance |
|---|---|---|---|---|
| **NGS vs. MFC** | GEM2000; GEM05 <65; GEM05 ≥65; GEM10 ≥65 [59] | 99 | clonoSEQ® NGS and MFC $10^{-5}$ | 83% (ρ 0.58) |
| | FORTE [20] | 335 ($10^{-5}$); 56 ($10^{-6}$) | clonoSEQ® NGS and MFC $10^{-5}$-$10^{-6}$ | At $10^{-5}$: 86% (ρ 0.61)<br>At $10^{-6}$: 78% (ρ 0.77) |
| | CASSIOPEIA [21] | 733 | clonoSEQ® NGS $10^{-6}$ and MFC $10^{-5}$ | 83.5% |
| | GMMG-HD6 [60] | 125 | clonoSEQ® NGS and MFC $10^{-5}$ | 68% |
| **NGS vs. NGF** | GEM2012MENOS65 [22] | 106 | LymphoTrack® NGS and NGF $10^{-5}$-$10^{-6}$ | 86% (ρ 0.905) |
| | GEM2012MENOS65 [61] | 104 | NGS and NGF $10^{-5}$-$10^{-6}$ | ρ 0.68 |
| **PET/CT vs. MFC vs. NGS** | FORTE [23] | 133 | NGS and MFC $10^{-5}$ | MFC<br>- FL: 63% concordance<br>- BM: 94% concordance<br><br>NGS<br>- FL: 63% concordance<br>- BM: 84% concordance<br><br>NGS and MFC<br>- BM: 84% concordance |

**Abbreviations**. MRD, minimal residual disease; N, number; pts, patients; MFC, multiparameter flow cytometry; NGS; next-generation sequencing; NGF, next-generation flow; FL, focal lesion; PET/CT, positron emission tomography/computed tomography; BM, bone marrow; ρ, Pearson's coefficient test, uptake.

**Table 2** Selected trials evaluating MRD-driven therapeutic modifications (only MRD-dependent treatment arms are discussed)

| Study | Patient population | Treatment scheme | MRD evaluation (technique) | Key MRD time point for decision making | Action type (intensification/ deintensification) | Therapy modification upon MRD results |
|---|---|---|---|---|---|---|
| UMCC 2018.056 (NCT04140162) | NDMM (ECOG 0-2, no significant cardiopulmonary disease) | Dara-Rd induction +/- Dara-VRd consolidation, and Dara-R-R maintenance | NA | Post induction (6 cycles) | Post-induction intensification in MRD-positive patients | Consolidation with Dara-VRd |
| PERSEUS (NCT03710603) [62] | TE NDMM | Dara-VRd induction, ASCT, Dara-VRd consolidation, Dara-R maintenance | NGS (clonoSEQ®) at $10^{-5}$ sensitivity | During maintenance | Deintensification if sustained MRD negativity confirmed in 2 evaluations at least after 1 year | Discontinuation of Dara after 2 years of maintenance and continuation of therapy with R maintenance alone |

| DRAMMATIC (NCT04071457) | TE NDMM after ASCT | Dara-R vs. R maintenance | NGS | After 2 years of maintenance | Randomization to deintensification vs. no deintensification in MRD-negative patients | Discontinuation of maintenance therapy after 2 years if MRD-negative evaluation and randomization to MRD-driven duration of maintenance |
|---|---|---|---|---|---|---|
| EMN20 (NCT04096066) | Fit or intermediate-fit NTE NDMM | KRd | NGS (clonoSEQ®) at $10^{-5}$ sensitivity | After 1 and 2 years of therapy | Deintensification if MRD-negative evaluation after 1 and 2 years of therapy | Discontinuation of K and continuation of therapy with Rd |
| MASTER (NCT03224507) [63] | NDMM (ECOG 0-2, CrCl ≥40 ml/min, no significant cardiopulmonary disease) | Dara-KRd induction, ASCT, Dara-KRd consolidation (0-8, number of cycles adapted to MRD status), R maintenance | NGS (clonoSEQ®) at $10^{-5}$ sensitivity | Post induction, post ASCT, post 4 consolidation cycles, post 8 consolidation cycles | Deintensification if 2 consecutive MRD-negative evaluations | Treatment discontinuation |
| RADAR (EudraCT 2019-001258-25) | Standard risk TE NDMM | CyVRd induction, ASCT, MRD-driven consolidation/ maintenance | NA | Post ASCT | Intensification or deintensification according to MRD status | MRD negativity: Isa maintenance (1 year) and then, if still MRD-negative status, randomization between continuation or discontinuation of Isa. MRD positivity: randomization to: 1) R maintenance; 2) VRd consolidation +R maintenance; 3) Isa-R maintenance; 4) Isa-VRd consolidation and Isa-R maintenance. |

**Abbreviations**. MRD, minimal residual disease; NDMM, newly diagnosed multiple myeloma; TE, transplant-eligible; ASCT, autologous stem-cell transplantation; ECOG, Eastern Cooperative Oncology Group performance status; CrCl, creatinine clearance; Dara, daratumumab; R, lenalidomide; d, dexamethasone; V, bortezomib; K, carfilzomib; Cy, cyclophosphamide; NA, not available; NGS, next-generation sequencing; Isa, isatuximab.

**Figure: title and legend**

**Fig. 1** Proposed model for selecting MRD assessment method on the basis of clinical presentation and response

**Abbreviations**. PET/CT, positron emission tomography/computed tomography; BM, bone marrow; MRD, minimal residual disease; NGS, next-generation sequencing; EMD, extramedullary disease; PB, peripheral blood; MS, mass spectrometry; NGF, next-generation flow; neg, negative; CA, chromosomal abnormalities; LDH, lactate dehydrogenase; ISS, International Staging System stage.

*Baseline PET/CT and BM sampling for MRD (if needed by technique; e.g., NGS)*

**A**

**Baseline presentation**

Patients with only **BM disease (no FL at PET/CT)**

→

**Initial MRD monitoring**

PB MRD (MS or NGF/NGS )

→

If PB MRD neg: perform BM MRD

↗ If BM MRD neg: need for sustained evaluation?

↘ If BM MRD pos: repeat at later timepoint (after a clinical phase? After a fixed duration of time?)

**B**

Patients with **EMD/focal lesions at PET/CT**

→

PB MRD (MS or NGF/NGS)

→

If PB MRD neg: perform PET/CT and BM MRD

↗ If BM MRD and PET/CT neg: need for sustained MRD

↘ If BM MRD pos: repeat at later time point (after a clinical phase? After a fixed duration of time?)

**C**

Patients with **circulating plasma cells**

→

PB MRD NGF (or MS/NGS)

→

If PB MRD neg: perform BM MRD and PET/CT

↗ If BM MRD and PET/CT neg: need for sustained MRD? Only PB monitoring?

↘ If BM MRD pos: repeat at later time point (after a clinical phase? After a fixed duration of time?)

For **high-risk patients**: high-risk CA, LDH, ISS II/III → consider multiple methods (imaging + BM)